Skip to content
Triangle logo TriangleGet started
← Gastric Cancer

HEALTH PROFESSIONAL · SOURCE READING

Pembrolizumab

Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 21, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage IV, Inoperable, and Recurrent Gastric Cancer / Treatment Options for Stage IV, Inoperable, and Recurrent Gastric Cancer / Third-line palliative systemic therapy / Immunotherapy

While pembrolizumab was previously evaluated as third-line treatment for patients with gastric and gastroesophageal junction cancers and a PD-L1 CPS of one or greater, this approval was withdrawn after updates to first-line therapy using combination chemotherapy and programmed death 1 (PD-1) inhibitors.

Preserved source evidence · Not medical advice